Tag: Denosumab
Biocon Biologics secures market entry date for Denosumab biosimilars in...
The agreement allows the company to commercialize both its Denosumab biosimilars (Vevzuo® and Evfraxy®) in Europe starting December 2, 2025
Lupin & I’rom enter into an exclusive licensing agreement for denosumab...
Following the completion of the clinical trial and receipt of marketing authorization from PMDA in Japan, I’rom will exclusively commercialize the product in Japan